via Infection Control Today
RMIT scientists in Melbourne have led an international collaboration that potentially unlocks better treatment of viral diseases, including the flu and common cold.
The results were published in the prestigious scientific and medical journal Nature Communications.
Each year the flu virus sends 13,500 Australians to hospital and causes more than 3000 deaths among those aged over 50. The global burden is also staggering, with more than 5 million cases of infection annually with up to 10 per cent resulting in death.
The RMIT senior authors, Dr Stavros Selemidis (ARC Future Fellow) and Dr Eunice To (first author), collaborated with Professor Doug Brooks from University South Australia, Professor John O’Leary from Trinity College Dublin, Monash University’s Professor Christopher Porter, and other scientists and clinicians to investigate how viruses cause disease in humans.
The researchers discovered that a 1.5 billion-year-old cell biological process found in plants, fungi and mammals enhances viral disease in mice and highly likely also in humans. They identified a protein, Nox2 oxidase, that is activated by viruses, including influenza, rhinovirus (the common cold), dengue and HIV.
Once activated, Nox2 oxidase suppresses the body’s key antiviral reaction and its ability to fight and clear the viral infection, which in turn results in a stronger or more virulent disease in mice.
The study also investigated a new prototype drug to treat these debilitating viral diseases.
The researchers found that the Nox2 oxidase protein activated by the viruses is located in a cell compartment called endosomes. They carefully modified a chemical that inhibits or restrains the activity of Nox2 oxidase.
Their customised drug was found to be very effective at suppressing disease caused by influenza infection.
Selemidis, head of the Oxidant and Inflammation Biology Group within the Chronic Infectious and Inflammatory Diseases program at RMIT, said: “Current treatment strategies are limited as they specifically target circulating viruses and have either unknown or very little effect against new viruses that enter the human population.
“We have identified a protein of the immune system that contributes to the disease caused by flu viruses irrespective of their strain.
“We also developed a novel drug delivery system to target this protein, which drastically alleviated the burden of viral disease.
“The strength of this work is the multidisciplinary approach taken and the degree of collaboration. It includes researchers and clinicians from eight universities across Australia, the United States and Ireland.
“This work attracted considerable interest at the NADPH Oxidase GORDON conference in the USA last year.”
To said: “This work identifies a treatment strategy that has the potential to alleviate the symptoms caused by some of the most devastating viruses worldwide, including the flu.”
Learn more: New research points to treatment breakthrough for viruses
The Latest on: Viral diseases
- Research shows a mother's fat intake can impact infant infectious disease outcomeson April 14, 2021 at 7:13 am
A team of UBC Okanagan researchers has determined that the type of fats a mother consumes while breastfeeding can have long-term implications on her infant's gut health.
- Ohio State Infectious Disease Specialist Calls Johnson & Johnson Vaccine Blood Clots 'Interesting and Rare'on April 14, 2021 at 6:58 am
Dr. Susan Koletar, the director of OSU’s division of infectious diseases at the Wexner Medical Center, explained the situation during Ohio Gov. Mike DeWine’s briefing Tuesday, saying that research ...
- Innovation Pharma’s Broad Spectrum Antiviral Drug Candidate Brilacidin Highlighted in Biodefense and Infectious Diseases COVID-19 Presentationon April 14, 2021 at 6:40 am
Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announced that Brilacidin, the Company’s defensin-mimetic drug candidate, was featured in the ...
- Researchers identify genes that make children susceptible to severe Kawasaki diseaseon April 14, 2021 at 6:30 am
Researchers have found genes that make children susceptible to the disease, and those associated with the heart damage it can cause in severe cases.
- Fauci warns of COVID-19 spread in youth sports — and parents call for better enforcement of virus protocolson April 14, 2021 at 6:20 am
Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases Large majorities of parents whose kids participated in one or more sports said their organization had informed ...
- Infectious disease experts caution public not to lose hope in COVID vaccines after Massachusetts halts use of Johnson & Johnson doseson April 14, 2021 at 2:47 am
For infectious disease experts like him, the recommendations from the Food and Drug Administration and the Center for Disease Control and Prevention show the federal oversight in action. “There are ...
- UBCO research shows a mother's fat intake can impact infant infectious disease outcomeson April 13, 2021 at 9:00 pm
"The goal was to investigate how maternal dietary habits can impact an offspring's gut microbial communities and their associated sugar molecule patterns which can be important in immune responses to ...
- Cincinnati infectious disease doctor answers questions about pause in J&J vaccinationson April 13, 2021 at 8:15 pm
During a memorial service at the US Capitol Rotunda for Officer William Evans, President Joe Biden picked up a toy dropped by the officer’s daughter, House Speaker Nancy Pelosi told his family that ...
- As variants spread, N.S. should 'pick up the pace' on testing, says infectious disease experton April 13, 2021 at 3:51 pm
With variants on the move in many parts of Canada, an infectious disease specialist says Nova Scotia should “pick up the pace” on developing more ways to test people for COVID-19, including take-home ...
- ‘Incredibly Rare Side Effect’: Infectious Disease Specialist Dr. Paul Sax Explains Johnson & Johnson Vaccine Pauseon April 13, 2021 at 11:10 am
BOSTON (CBS) – Based on recommendations by the FDA and CDC, Massachusetts, New Hampshire, as well as federal vaccine programs at local pharmacies paused further injections of the Johnson & Johnson ...
via Google News and Bing News